Zynerba Pharmaceuticals Stock (NASDAQ:ZYNE)
Previous Close
$1.27
52W Range
$0.25 - $1.40
50D Avg
$1.12
200D Avg
$0.61
Market Cap
$70.12M
Avg Vol (3M)
$1.04M
Beta
1.19
Div Yield
-
ZYNE Company Profile
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
ZYNE Performance
Peer Comparison
| Ticker | Company |
|---|---|
| DRRX | DURECT Corporation |
| LSDI | Lucy Scientific Discovery Inc. |
| ACOR | Acorda Therapeutics, Inc. |
| SXTC | China SXT Pharmaceuticals, Inc. |
| COLL | Collegium Pharmaceutical, Inc. |
| EGRX | Eagle Pharmaceuticals, Inc. |
| ITCI | Intra-Cellular Therapies, Inc. |
| EBS | Emergent BioSolutions Inc. |
| PAHC | Phibro Animal Health Corporation |
| DCPH | Deciphera Pharmaceuticals, Inc. |
| HUGE | FSD Pharma Inc. |
| IMCC | IM Cannabis Corp. |